A5013793634- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Genomics and Rare Diseases
- Carcinogens and Genotoxicity Assessment
- Synthesis of Tetrazole Derivatives
- Lymphoma Diagnosis and Treatment
- Genomics, phytochemicals, and oxidative stress
- Free Radicals and Antioxidants
- Pancreatic and Hepatic Oncology Research
University of Freiburg
2022-2023
University of Copenhagen
2021
Abstract Background Current therapeutic management of advanced melanoma patients largely depends on their BRAF mutation status. However, the vast heterogeneity tumors hampers success therapies targeting MAPK/ERK pathway alone. Dissecting this will contribute to identifying key players in oncogenic progression tailor more effective therapies. Methods We performed a comprehensive molecular and phenotypic characterization panel patient-derived V600E -positive cell lines. Transcriptional...
Humans have extensive adverse exposure to alpha,beta-unsaturated carbonyl compounds (ABuCs) as these are major toxins in smoke and exhaust fumes, well products of lipid peroxidation. In contrast, another ABuC, dimethylfumarate, is used treat psoriasis multiple sclerosis. ABuCs undergo Michael adduction with amine, imidazole thiol groups, reaction at Cys residues predominating. Here we report rate constants, k2, for (acrolein, crotonaldehyde, cyclohex-1-en-2-one, cyclopent-1-en-2-one) present...
(1) Background: Next-generation sequencing (NGS) of patients with advanced tumors is becoming an established method in Molecular Tumor Boards. However, somatic variant detection, interpretation, and report generation, require in-depth knowledge both bioinformatics oncology. (2) Methods: MIRACUM-Pipe combines many individual tools into a seamless workflow for comprehensive analyses annotation NGS data including quality control, alignment, calling, copy number variation estimation, evaluation...
Abstract Current therapeutic management of advanced melanoma patients largely depends on their BRAF mutation status. However, the vast heterogeneity tumors hampers success therapies targeting MAPK/ERK pathway alone. Dissecting this will contribute to identifying key players in oncogenic progression tailor more effective therapies. We performed a comprehensive molecular and phenotypic characterization panel patient-derived V600E -positive cell lines. Transcriptional profiling was used...